Your browser doesn't support javascript.
loading
Impact of Preoperative Chronic Kidney Disease in 2,531 High-Risk and Inoperable Patients Undergoing Transcatheter Aortic Valve Replacement in the PARTNER Trial.
Thourani, Vinod H; Forcillo, Jessica; Beohar, Nirat; Doshi, Darshan; Parvataneni, Rupa; Ayele, Girma M; Kirtane, Ajay J; Babaliaros, Vasilis; Kodali, Susheel; Devireddy, Chandan; Szeto, Wilson; Herrmann, Howard C; Makkar, Raj; Ailawadi, Gorav; Lim, Scott; Maniar, Hersh S; Zajarias, Alan; Suri, Rakesh; Tuzcu, E Murat; Kapadia, Samir; Svensson, Lars; Condado, Jose; Jensen, Hanna A; Mack, Michael J; Leon, Martin B.
Afiliação
  • Thourani VH; Emory University School of Medicine, Atlanta, Georgia. Electronic address: vthoura@emory.edu.
  • Forcillo J; Emory University School of Medicine, Atlanta, Georgia.
  • Beohar N; Columbia University Division of Cardiology, Mount Sinai Medical Center, Miami Beach, Florida.
  • Doshi D; Columbia University Medical Center, New York, New York.
  • Parvataneni R; Cardiovascular Research Foundation, New York, New York.
  • Ayele GM; Cardiovascular Research Foundation, New York, New York.
  • Kirtane AJ; Columbia University Medical Center, New York, New York; Cardiovascular Research Foundation, New York, New York.
  • Babaliaros V; Emory University School of Medicine, Atlanta, Georgia.
  • Kodali S; Columbia University Medical Center, New York, New York; Cardiovascular Research Foundation, New York, New York.
  • Devireddy C; Emory University School of Medicine, Atlanta, Georgia.
  • Szeto W; University of Pennsylvania, Philadelphia, Pennsylvania.
  • Herrmann HC; University of Pennsylvania, Philadelphia, Pennsylvania.
  • Makkar R; Cedars-Sinai Medical Center, Los Angeles, California.
  • Ailawadi G; University of Virginia, Charlottesville, Virginia.
  • Lim S; University of Virginia, Charlottesville, Virginia.
  • Maniar HS; Washington University, St. Louis, Missouri.
  • Zajarias A; Washington University, St. Louis, Missouri.
  • Suri R; Cleveland Clinic, Cleveland, Ohio.
  • Tuzcu EM; Cleveland Clinic, Cleveland, Ohio.
  • Kapadia S; Cleveland Clinic, Cleveland, Ohio.
  • Svensson L; Cleveland Clinic, Cleveland, Ohio.
  • Condado J; Emory University School of Medicine, Atlanta, Georgia.
  • Jensen HA; Emory University School of Medicine, Atlanta, Georgia.
  • Mack MJ; Baylor, Scott, and White Healthcare, Plano, Texas.
  • Leon MB; Columbia University Medical Center, New York, New York; Cardiovascular Research Foundation, New York, New York.
Ann Thorac Surg ; 102(4): 1172-80, 2016 Oct.
Article em En | MEDLINE | ID: mdl-27592092
ABSTRACT

BACKGROUND:

Although preoperative renal dysfunction (RD) is associated with increased mortality and morbidity after surgical aortic valve replacement, its impact on clinical outcomes after transcatheter aortic valve replacement (TAVR) is less defined.

METHODS:

TAVR patients in the PARTNER (Placement of Aortic Transcatheter Valves) trial with a calculable glomerular filtration rate (GFR) using the Modification of Diet in Renal Disease equation were included. Patients were divided into three groups GFR >60 mL/min (none/mild RD), GFR 31 to 60 mL/min (moderate RD), and GFR ≤30 mL/min (severe RD). Operative characteristics and clinical outcomes were analyzed. Cox regression models were used to determine multivariable predictors of 1-year all-cause mortality.

RESULTS:

A total of 2,531 inoperable or high surgical risk patients from the PARTNER trial and continued access registries had a calculable GFR level 767 (30%) had normal renal function or mild RD, 1,473 (58%) had moderate RD, and 291 (12%) presented with severe RD. The mean Society of Thoracic Surgeons Predicted Risk of Mortality for the cohort was 11.5%, and it was highest in those with severe RD (13.8%). Patients with severe RD were more often women with a higher prevalence of diabetes. Patients with severe RD had the highest incidence of 30-day and 1-year all-cause mortality and rehospitalization. The 30-day rate of death from any cause was 10.7% in the severe RD group versus 6.0% in the moderate and mild RD groups (p = 0.01). The 1-year rate of death from any cause was 34.4% in the severe RD group versus 21.5% in the moderate RD and 20.8% in the none/mild RD groups (adjusted hazard ratio [HR] 2.24, p < 0.0001 for severe versus none/mild; adjusted HR 1.14, p = 0.24 for severe versus moderate). Other significant predictors of 1-year all-cause mortality included lower body mass index, frailty, the transapical approach, a lower ejection fraction, oxygen-dependent chronic obstructive pulmonary disease, liver disease, and male sex.

CONCLUSIONS:

Preoperative severe RD is a significant predictor for 1-year mortality in TAVR patients. Careful risk stratification by the heart team is required in patients with severe preprocedural RD.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Causas de Morte / Substituição da Valva Aórtica Transcateter / Falência Renal Crônica Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans Idioma: En Revista: Ann Thorac Surg Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estenose da Valva Aórtica / Causas de Morte / Substituição da Valva Aórtica Transcateter / Falência Renal Crônica Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans Idioma: En Revista: Ann Thorac Surg Ano de publicação: 2016 Tipo de documento: Article